Professor Jiahai Lu, from School of Public Health, Sun Yat-Sen University, is currently a PhD supervisor on Epidemiology and Microbiology as well as a principal investigator (PI) in the Laboratory for Tropical Disease Control and Prevention and Guangdong Provincial Research Center for Severe Infectious Disease Prevention and Control Technology. His particular field of interest includes vaccinology, epidemiology on infectious diseases, and prevention and control on zoonotic diseases. He has published more than 150 peer-reviewed papers on influential journals home and abroad such as Science, Physiological Genomics, Respiratory Research, Vaccine and BMC Infectious Diseases and more than 30 papers have been cited by SCI, among which he served as the first author or corresponding author. Besides, He acts as the editorial board member of journals in China like Chinese Medical Journal, Chinese Journal of Preventive Medicine and International Journal of Virology as well as the reviewer of some international journals like Vaccine and BMC Infections diseases.
Research:
Recently, Professor Jiahai Lu’s projects mainly relate to control and prevention strategies on emerging infectious diseases like influenza, EV71 virus and Chikungunya virus. These include:
1. Key technology for zoonosis control and prevention based on One Health concept (funded by Guangzhou Science and technology plan project, 2015-2017)
2. Glycomics study on cross-species transmission and pathogenic mechanism of H7N9 virus (funded by Guangdong Province Science and technology plan project, 2013B051000033, 2014-2016)
3. Immunologic and infectious mechanism of chikungunya virus based on virus-like particles (VLPs) technology (funded by The National Natural Science Foundation of China, 81373050, 2014-2017)
4. Experimental study on construction of chikungunya virus-like particles (funded by Natural Science Foundation of Guangdong Province, China, 2013－2015)
5. Mechanism and epidemiological evidence research on anti-influenza effect of statins (funded by The National Natural Science Foundation of China, 81172735, 2012-2015)
6. Preclinical study on anti-influenza effect of statin/caffeine (funded by Guangdong Province Science and technology plan project, 2010B031600076, 2012-2014)
7. Preclinical study on virus-like particle vaccine for EV71 virus (funded by major projects, Health Bureau of medical and health science and technology of Guangzhou city, 2011-2013)
Listed below is a selection of Professor Jiahai Lu's publications:
[1] Ma M, Anderson BD, Wang T, Chen Y, Zhang D, Gray GC, Lu J: Serological Evidence and Risk Factors for Swine Influenza Infections among Chinese Swine Workers in Guangdong Province[J]. PLoS One 2015, 10(5):e128479.
[2] Wang T, Wang M, Shu B, Chen XQ, Luo L, Wang JY, Cen YZ, Anderson BD, Merrill MM, Merrill HR et al: Evaluation of inapparent dengue infections during an outbreak in Southern China[J]. PLoS Negl Trop Dis 2015, 9(3):e3677.
[3] Su S, Gray GC, Lu J, Liao M, Zhang G, Li S: New "One Health" strategies needed for detection and control of emerging pathogens at Cantonese live animal markets, China[J]. Clin Infect Dis 2014, 59(8):1194-1197.
[4] Peng J, Zhang D, Ma Y, Wang G, Guo Z, Lu J: Protective effect of fluvastatin on influenza virus infection[J]. Mol Med Rep 2014, 9(6):2221-2226.
[5] Zhang Z, Xia Y, Lu Y, Yang J, Zhang L, Su H, Lin L, Wang G, Wang T, Lin S et al: Prediction of H7N9 epidemic in China[J]. Chin Med J (Engl) 2014, 127(2):254-260.
[6] Elbadry MA, Merrill MM, Ma MM, Ma MJ, Lu JH, Cao WC, Gray GC: China's great wall, Israel's Bar Lev Line, and passive infectious disease surveillance[J]. Mil Med Res 2014, 1:15.
[7] Zhang DM, Ma MM, Wen WT, Zhu X, Xu L, He ZJ, He X, Wu JH, Hu YW, Zheng Y et al: Clinical epidemiology and molecular profiling of human bocavirus in faecal samples from children with diarrhoea in Guangzhou, China[J]. Epidemiol Infect 2014:1-15.
[8] Ma Y, Wen X, Peng J, Lu Y, Guo Z, Lu J: Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality[J]. PLoS One 2012, 7(12):e51548.
[9] Jing QL, Yang ZC, Luo L, Xiao XC, Di B, He P, Fu CX, Wang M, Lu JH: Emergence of dengue virus 4 genotype II in Guangzhou, China, 2010: survey and molecular epidemiology of one community outbreak[J]. Bmc Infect Dis 2012, 12:87.
[10] Zhang D, Lu J, Lu J: Enterovirus 71 vaccine: close but still far[J]. Int J Infect Dis 2010, 14(9):e739-e743.
[11] Liu Z, Guo Z, Wang G, Zhang D, He H, Li G, Liu Y, Higgins D, Walsh A, Shanahan-Prendergast L et al: Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice[J]. Eur J Pharm Sci 2009, 38(3):215-223.
[12] Lu CY, Lu JH, Chen WQ, Jiang LF, Tan BY, Ling WH, Zheng BJ, Sui HY: Potential infections of H5N1 and H9N2 avian influenza do exist in Guangdong populations of China[J]. Chin Med J (Engl) 2008, 121(20):2050-2053.
[13] Si H, Guo ZM, Hao YT, Liu YG, Zhang DM, Rao SQ, Lu JH: Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province[J]. Bmc Infect Dis 2008, 8:113.
[14] Zhang DM, Lu JH, Zhong NS: Pathogenesis of severe acute respiratory syndrome[J]. Chin Med J (Engl) 2008, 121(17):1722-1731.
[15] Liao JW, Lu JH, Guo ZM, Wang GL, Zhang DM, Chen LJ, Zheng HY, Zhong NS: A retrospective serological study of severe acute respiratory syndrome cases in Guangdong province, China[J]. Chin Med J (Engl) 2007, 120(8):718-720.
[16] Guo ZM, Lu JH, Han WY, Liu ZY, Li GW, Liao JW, Wang SM, Wu YS, Zheng HY, Zhong NS et al: Comparison of effectiveness of whole viral, N and N199 proteins by ELISA for the rapid diagnosis of severe acute respiratory syndrome coronavirus[J]. Chin Med J (Engl) 2007, 120(24):2195-2199.
[17] Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X: Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice[J]. Respir Res 2006, 7:43.
[18] Lu JH, Zhang DM, Wang GL: Highlight the significance of genetic evolution of H5N1 avian flu[J]. Chin Med J (Engl) 2006, 119(17):1458-1464.
[19] Zhang CH, Lu JH, Wang YF, Zheng HY, Xiong S, Zhang MY, Liu XJ, Li JX, Wan ZY, Yan XG et al: Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain[J]. Vaccine 2005, 23(24):3196-3201.
[20] Lu JH, Zhang DM, Wang GL, Guo ZM, Li J, Tan BY, Ou-Yang LP, Ling WH, Yu XB, Zhong NS: Sequence analysis and structural prediction of the severe acute respiratory syndrome coronavirus nsp5[J]. Acta Biochim Biophys Sin (Shanghai) 2005, 37(7):473-479.
[21] Lu JH, Guo ZM, Han WY, Wang GL, Zhang DM, Wang YF, Sun SY, Yang QH, Zheng HY, Wong BL et al: Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus[J]. Acta Pharmacol Sin 2005, 26(12):1479-1484.
[22] Zhang DM, Wang GL, Lu JH: Severe acute respiratory syndrome: vaccine on the way[J]. Chin Med J (Engl) 2005, 118(17):1468-1476.
[23] Lu JH, Zhang DM, Wang GL, Guo ZM, Zhang CH, Tan BY, Ouyang LP, Lin L, Liu YM, Chen WQ et al: Variation analysis of the severe acute respiratory syndrome coronavirus putative non-structural protein 2 gene and construction of three-dimensional model[J]. Chin Med J (Engl) 2005, 118(9):707-713.
[24] Zhang CH, Wang YF, Liu XJ, Lu JH, Qian CW, Wan ZY, Yan XG, Zheng HY, Zhang MY, Xiong S et al: Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro[J]. Chin Med J (Engl) 2005, 118(6):493-496.
[25] Wang D, Lu J: Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV[J]. Physiol Genomics 2004, 18(2):245-248.
[26] He J F, Peng G W, Min J, Yu D W, Liang W J, Zhang S Y, Xu R H, Zheng H Y, Wu X W, Xu J, Wang Z H, Fang L, Zhang X, Li H, Yan X G, Lu J H, Hu Z H, Huang J F, Wan Z Y, Hou J L, Lin J Y, Song H D, Wang S Y, Zhou X J, Zhang G W, Gu B W, Zheng H J, Zhang X L, He M, Zheng K, Wang B F, Fu G, Wang X N, Chen S J, Chen Z, Hao P, Tang H, Ren S X, Zhong Y, Guo Z M, Liu Q, Miao Y G, Kong X Y, He W Z, Li Y X, Wu C, Zhao G P, Chiu Rossa W K, Chim Stephen S C, Yu-Kwan T, Chan Paul K S, Tam John S, Dennis L Y M. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China[J]. Science 2004, 303(5664):1666-1669.
[27] Zhang CH, Guo ZM, Zheng HY, Lu JH, Wang YF, Yan XG, Zhao Y, DU XW, Zhang X, Fang L et al: Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain[J]. Chin Med J (Engl) 2004, 117(11):1625-1629.
[28] Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, Qian CW, Li JX, Lu JH, Wan ZY et al: Immunogenicity of SARS inactivated vaccine in BALB/c mice[J]. Immunol Lett 2004, 95(2):139-143.
[29] Zhang R, Guo Z, Lu J, Meng J, Zhou C, Zhan X, Huang B, Yu X, Huang M, Pan X et al: Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA[J]. Chin Med J (Engl) 2003, 116(8):1262-1264.
